The HER2-Positive Breast Cancer Market encompasses a range of targeted therapeutics designed to inhibit the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in approximately 20–25% of breast cancer cases. Key products include monoclonal antibodies (trastuzumab, pertuzumab), antibody–drug conjugates (ado-trastuzumab emtansine), tyrosine kinase inhibitors (lapatinib, neratinib) and emerging biosimilars and biobetters. These therapies offer significant advantages over conventional chemotherapy by specifically binding to HER2 receptors, thereby reducing off-target toxicity and improving progression-free survival and overall response rates.

The need for these products is driven by rising incidence of HER2-positive tumors, unmet clinical HER2-Positive Breast Cancer Market demand for less toxic regimens, and the push toward personalized medicine. Advances in diagnostic tests also support early detection of HER2 overexpression, enabling more precise patient stratification. Furthermore, growing regulatory approvals and robust market research into novel drug combinations are enhancing the market scope.

The HER2-Positive Breast Cancer Market is estimated to be valued at USD 10.96 bn in 2025 and is expected to reach USD 12.94 bn by 2032, growing at a compound annual growth rate (CAGR) of 2.4% from 2025 to 2032.

Key Takeaways

Key players operating in the HER2-Positive Breast Cancer Market are Jiangsu HengRui Medicine Co., Ltd., Shanghai Henlius Biotech, Merus N.V., GeneQuantum, and Roche. These market players hold substantial industry share, thanks to their diversified portfolios of branded biologics and biosimilars. For instance, Roche’s landmark monoclonal antibody suite continues to dominate market revenue, while Jiangsu HengRui and Shanghai Henlius are making inroads with cost-effective biosimilars. Merus N.V. and GeneQuantum bring novel bispecific antibodies and next-generation ADCs into late-stage clinical trials. Strategic collaborations, licensing agreements, and co-development pacts among these companies are vital components of their market growth strategies. Their strong R&D pipelines, coupled with extensive global distribution networks, underpin competitive dynamics and shape the overall market structure.

➢Get More Insights On: HER2-Positive Breast Cancer Market

➢Get this Report in Japanese Language:  HER2陽性乳がん市場

➢Get this Report in Korean Language: HER2양성유방암시장